Pilot studies of various combinations of dibromodulcitol, VP-16, and AMSA.
Pilot studies to obtain drug dosages for the combinations of dibromodulcitol (DBD) and BP-16, DBD and AMSA, and DBD, VP-16 and AMSA were carried out to levels of acceptable clinical toxicity. Myelosuppression was the dose-limiting toxicity in all combinations. While regressions were few in this group of heavily pretreated patients, we feel the drug combinations need further study in central nervous system, breast, and lung cancers.
D000368:Aged; D000609:Aminoacridines / Q000008:administration & dosage / Q000633:toxicity*; D000677:Amsacrine; D004341:Drug Evaluation; D004359:Drug Therapy, Combination; D005047:Etoposide / Q000008:administration & dosage / Q000633:toxicity*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D008936:Mitolactol / Q000008:administration & dosage / Q000633:toxicity*; D009369:Neoplasms / Q000188:drug therapy*; D010865:Pilot Projects; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D000609:Aminoacridines; D000677:Amsacrine; D005047:Etoposide; D011034:Podophyllotoxin; D008936:Mitolactol